Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes
This study is currently recruiting patients.
Sponsored by: | FDA Office of Orphan Products Development |
---|---|
Information provided by: | FDA Office of Orphan Products Development |
Purpose
This is a study to determine the response rate in patients with myelodysplastic syndromes treated with calcitriol and dexamethasone.
Condition | Treatment or Intervention | Phase |
---|---|---|
Myelodysplastic Syndromes |
Drug: Calcitriol Drug: Dexamethasone |
Phase II |
MedlinePlus related topics: Bone Marrow Diseases
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Dose Comparison, Safety/Efficacy Study
Official Title: Calcitriol and Dexamethasone for Myelodysplastic Syndromes
Expected Total Enrollment: 60
Study start: September 2001;
Study completion: September 2004
Current therapeutic options for myelodysplastic syndromes (MDS) are limited and, aside from bone marrow transplantation, none have proven superior to supportive measures alone. Preclinical investigations have indicated the potential therapeutic role for vitamin D in the treatment of MDS. However, because of the dose-limiting toxicity of hypercalcemia, past clinical trials with vitamin D have been forced to utilize low doses, with promising but inconsistent results.
This study utilizes a dosing schema of dexamethasone (Dex) and calcitriol (the active form of vitamin D) that augments the therapeutic index of calcitriol, and allows for safe administration of 5-10 times higher dose of calcitriol than previously has been used in clinical trials for MDS. Patients will receive dexamethasone 4 times per week and calcitriol 3 times per week. This schedule will continue weekly until patients are off study. The dose of calcitriol will be increased until the maximum tolerated dose (MTD) is determined. History and physical examination, blood monitoring, urinary ultrasounds, and bone marrow aspirations and biopsies will be used to assess disease response.
Eligibility
Genders Eligible for Study: Both
Criteria
Inclusion criteria:
Exclusion criteria:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |